



Notice of Extraordinary Shareholders' Meeting on 7th September 2020 Regarding Proposed Warrant Plans

Liège, Belgium, 7 August 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, today announces the publication of the invitation to its Extraordinary General Shareholders' Meeting (EGM) that will be held on Monday September 7 2020 at 2:00 PM (CET) in Flémalle 57 rue de l'Expansion (Belgium).

This Extraordinary General Meeting follows the Extraordinary General Meeting which was held on July 22, 2020 and during which the attendance quorum required for some resolutions (namely, the resolutions referred to in points 3 to 5 of the agenda detailed in the corporate documents appended to the invitation) has not been reached. It is convened based on Article 7: 153 paragraph 3 of the Companies and Associations Code.

The agenda of this Meeting will mainly consider the issuance of two warrant plans, only one of which is yet subject to the shareholder's approval: (i) one for the benefit of LDA Capital Ltd whereby a maximum of 690,000 warrants would be issued within the framework of the transaction announced on the 24th April 2020¹ which has already been approved by the Extraordinary Shareholders' meeting of 22nd July 2020, and (ii) another for the benefit of reference shareholders ("Share Lending Warrants") as further detailed in the supporting documentation for a maximum of 300,000 warrants.

The special reports of the board of directors and of the statutory auditor established pursuant to provisions 7:180, 7: 191 and 7:193 of the Belgian Companies and Associations Code, the notice for the EGM for the shareholders, including all details on how to participate to this Meeting and the supporting documents are available on [the Company website](#).

For more information, please contact:

Alexandra Deschner (IRO) : +32 490 58 35 23 - investorrelations@mithra.com

Carole Kousis (Presse) : +32 4 349 28 22 – press@mithra.com

About Mithra

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Its three lead development candidates are built on Mithra's unique native estrogen platform, Estetrol (E4): Estelle®, a new era in oral contraception, PeriNesta®, the first complete oral treatment targeting perimenopause and Donesta®, the next-

¹ [Mithra Press Release](#), 24/04/2020

generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 250 staff members and is headquartered in Liège, Belgium. www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be req

uired by law.



Subscribe to our mailing list on investors.mithra.com to receive our press releases by email or follow us on our social media :

[Linkedin](#) • [Twitter](#) • [Facebook](#)